Oluyemi Okupe Sells 55,383 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Key Points

• CFO Oluyemi Okupe sold 55,383 Hims & Hers shares at an average price of $35.09, worth approximately $1.94 million. The sale was conducted under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity awards, reducing his direct holdings by 19.48%.
• Hims & Hers shares recently traded at $27.43, well below the sale price, with a 52-week range of $13.74 to $65.30. The company reported revenue of $753.21 million, up 38.2% year over year, but missed earnings expectations with a quarterly loss of $0.37 per share.
• Analysts maintain a consensus “Hold” rating, with a consensus price target of $32.43. Four analysts rate the stock Buy, eleven Hold, and one Sell, while institutional investors own 63.52% of the shares.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 55,383 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.09, for a total value of $1,943,389.47. Following the sale, the chief financial officer directly owned 228,938 shares in the company, valued at $8,033,434.42. This trade represents a 19.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $1.19 on Tuesday, reaching $27.43. The stock had a trading volume of 7,895,463 shares, compared to its average volume of 26,328,367. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market cap of $6.40 billion, a P/E ratio of -43.53 and a beta of 2.40. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The business's 50 day moving average is $32.14 and its two-hundred day moving average is $26.05.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HIMS shares. UBS Group set a $23.00 price objective on Hims & Hers Health in a research report on Friday, May 22nd. Needham & Company LLC upped their target price on Hims & Hers Health from $35.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Hims & Hers Health in a report on Friday, August 7th. Morgan Stanley boosted their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 11th. Finally, Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $32.43.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company's stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. State Street Corp raised its position in Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company's stock worth $237,210,000 after purchasing an additional 132,311 shares during the period. Geode Capital Management LLC raised its position in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company's stock worth $183,485,000 after purchasing an additional 608,950 shares during the period. Bank of America Corp DE lifted its stake in Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company's stock worth $235,525,000 after buying an additional 1,600,004 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source